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Abstract
High-dose vitamin A supplementation (VAS) may affect mortality to infectious diseases in a sex-differential manner. Here, we analysed the
long-term immunological effects of neonatal vitamin A supplementation (NVAS) in 247 children, who had been randomly allocated to 50 000
or 25 000 IU vitamin A (15mg and 7·5mg retinol equivalents, respectively) or placebo at birth. At 4–6 months of age, we assessed bacille
Calmette–Guérin (BCG) scariﬁcation, and we analysed in vitro responses of TNF-α, IL-5, IL-10, IL-13 and IFN-γ in whole blood stimulations to
phytohaemagglutinin (PHA), puriﬁed protein derivative (PPD), tetanus toxoid and lipopolysaccharide. There were no differences between the
two doses of NVAS, and thus they were analysed combined as NVAS (any dose) v. placebo. All analyses were performed unstratiﬁed and by
sex. NVAS increased the chance of having a scar after BCG vaccination in females (NVAS v. placebo: 96 v. 71%, proportion ratio: 1·24; 95% CI
1·09, 1·42), but not in males (Pfor interaction= 0·012). NVAS was associated with signiﬁcant sex-differential effects on the pro- to anti-
inﬂammatory cytokine ratios (TNF-α:IL-10) to PPD, tetanus toxoid and medium alone, which were increased in females but decreased in
males. In addition, IL-17 responses tended to be increased in NVAS v. placebo recipients in males but not in females, signiﬁcantly so for the
PHA stimulation. The study corroborates sex-differential effects of VAS on the immune system, emphasising the importance of analysing VAS
effects by sex.
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Vitamin A and its metabolites are essential for the functioning of
the immune system(1). Vitamin A supplementation (VAS) is
recommended for children from 6 months to 5 years of age in
populations with high risk of vitamin A deﬁciency (VAD) to
reduce VAD-related morbidity and mortality(2). High-dose
VAS in the neonatal period (NVAS) is not WHO policy but
has been tested in several randomised controlled trials (RCT)
and is currently being considered as a policy, at least for
sub-groups(3,4). Our research group in Guinea-Bissau has
conducted several of the NVAS trials, and found that NVAS
had sex-differential effects on mortality, being associated
with slightly lower mortality in males, but higher mortality in
females(5–7). The negative effect in females increased with
increasing length of follow-up, and other studies have indeed
corroborated this pattern; in all existing trials with follow-up to
12 months of age, females who had received NVAS had higher
mortality than females who had received placebo at birth from 6
to 12 months of follow-up(8). We have hypothesised that this
could be due to a negative interaction between NVAS and
subsequent diphtheria–tetanus–pertussis (DTP) vaccination
(recommended in three doses at 6, 10 and 14 weeks of age) in
females(8,9). This observation is epidemiologically founded.
Explorative immunological studies may generate hypotheses,
which could guide the design of further mechanistic studies.
In the present explorative study, we took advantage of
two existing trial cohorts to assess sex differences in the
Abbreviations: BCG, bacille Calmette–Guérin; DTP, diphtheria–tetanus–pertussis vaccine; GMR, geometric:mean ratio; MV, measles vaccine; NVAS, neonatal
vitamin A supplementation; PPD, puriﬁed protein derivative from Mycobacterium tuberculosis; RCT, randomised controlled trial; VAS, vitamin A
supplementation.
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immunological response to NVAS, which could help explain the
sex differences in the mortality effects.
The early measles vaccine (MV) trial was a RCT testing the
effect of providing an additional dose of early (i.e. 4–6 months
of age) dose of MV in Guinea-Bissau, West Africa. Children
were enrolled at the age of 4–6 months after the third dose of
DTP and randomised to early MV or no early MV in addition to
the usual MV at the age of 9 months (Fig. 1)(10). Before ran-
domisation, a blood sample was collected from a subgroup of
the children for an immunological study(11). Independent of the
early MV trial, some participants had previously participated in
an RCT of NVAS(6). Using the blood samples collected as a
baseline in the early MV trial (before allocation to early MV or
no early MV)(11), we analysed the association between NVAS
and in vitro cytokine responses in the 4- to 6-month-old infants
who had participated also in the NVAS trial.
Methods
Setting
The study took place at the Bandim Health Project in Guinea-
Bissau (www.bandim.org), which follows a population of about
100 000 people in a health and demographic surveillance system.
The study was deﬁned by two existing trial cohorts, involving a
group of children who had participated in ﬁrst an NVAS trial, and
then, independent of the NVAS trial, participated in the early MV
trial, including an immunological MV sub-group study(11).
Neonatal vitamin A supplementation trial
From 2004 to 2008, an RCT of NVAS was conducted in the study
area randomising normal-birth weight (>2500 g) infants 1:1:1 to
receiving 15mg retinol equivalents (RE) (50 000 IU vitamin A),
7·5mg RE (25 000 IU vitamin A) or placebo at birth; all received
concurrently bacille Calmette–Guérin (BCG) vaccine(6).
Early measles vaccine trial
From 2003 to 2007, an RCT of early MV was conducted, testing
the effect on mortality of giving an additional MV earlier than
the generally recommended MV at 9 months of age(10). In brief,
infants who had received three scheduled DTP vaccinations
were eligible for enrolment and randomisation to early MV
(Edmonston-Zagreb) at 4–6 months of age or no early MV (all
infants were to receive the recommended MV at 9 months).
Thus, at enrolment, infants had DTP3 + oral polio vaccine 3 as
their last vaccines.
Immunological measles vaccine sub-group study
The immunological MV sub-group study to investigate the non-
speciﬁc immunological effects of MV (clinicaltrials.gov: no.
NCT00168545) took place in 2006. From January through Sep-
tember 2006, immediately before randomisation to early MV or
no early MV at 4·5 months of age, a physician examined chil-
dren for eligibility. To avoid that acute illness inﬂuenced plasma
biomarkers and stimulated cytokine production, children with
the following characteristics were excluded from the immuno-
logical study: current fever or diarrhoea reported by the mother;
an axillary temperature above 37·5°C; a respiratory rate at 60/
min or above; or current infection diagnosed by the physician.
BCG scariﬁcation was assessed and a blood sample was taken
by ﬁnger prick. The present study is based on this baseline (pre-
MV) sample from the early MV trial. Some children had a
venous instead of capillary blood sample obtained, but we
excluded venous samples because we found differences in the
cytokine responses in venous and capillary blood(12). Analytical
details can be found in(11). In brief, whole blood
was diluted 1:9 with RPMI-1640 containing streptomycin
(100mg/ml), penicillin A (100 IU/ml), glutamate (2mM) and
pyruvate (1mM) (all Gibco). The diluted blood was stimulated
with lipopolysaccharide (LPS, 1 ng/ml; Sigma-Aldrich)
(a Toll-like receptor (TLR)4 ligand), (S)-(2,3-bis-(palmitoyloxy)-
(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys4-OH, trihydro-
chloride (Pam3CSK4, 100 ng/ml; Cayla-InvivoGen Europe, a
TLR2 ligand), phytohaemagglutinin (PHA, 2 μg/ml; Wellcome
Diagnostics), tetanus toxoid (TT, 1·5 Lf/ml), puriﬁed protein
derivative (PPD) from Mycobacterium tuberculosis (10 μg/ml;
Statens Serum Institut) or medium alone. Concentrations of
cytokines were measured from supernatants using the Luminex
platform (Luminex 100; Luminex Corp.) (lower limit of
detection (LLD) given in parenthesis): TNF-α (10 pg/ml), IFN-γ
(5 pg/ml), IL-5 (3 pg/ml), IL-10 (5 pg/ml), IL-13 (10 pg/ml) and
IL-17 (10 pg/ml) (BioSource). In unstimulated plasma, con-
centrations of the following compounds were measured using
the Luminex assay kit (Fluorokine MAP Multiplex Human
Cytokine Panel A; R&D Systems): TNF-α (LLD: 5 pg/ml), IL-10
(5 pg/ml), IL-6 (7 pg/ml), monocyte chemoattractant chemokine
protein (MCP)-1 (10 pg/ml), IL-8 (2·8 pg/ml) and IL-1Ra (30 pg/
ml); concentrations of soluble urokinase plasminogen activator
receptor (suPAR) was measured by ELISA (suPARnostic stan-
dard ELISA, ViroGates)(11).
Statistical methods have been described previously(11).
Cytokine data were log-transformed and analysed with Tobit
regression using multiple imputations to account for measure-
ments below the LLD of the assay, and estimates were back-
transformed providing geometric mean ratios (GMR). Where
>50% of measurements were below the LLD of the respective
analytes, Poisson regression was used, providing proportion
ratios (PR) of measurements above LLD as done pre-
viously(13,14). A summary of the proportion of measurements
>50% and the geometric means can be found in the online
Supplementary Table S1.
For distributions with <50% observations below LLD, the
ratios of IFN-γ to IL-5, IFN-γ to IL-10 and TNF-α to IL-10 were
analysed and reported as GMR-ratios (GMRR).
Exploratory data analysis indicated that there was no differ-
ence in the effect of 7·5mg RE v. 15mg RE overall or stratiﬁed
by sex; hence, the two doses were analysed collectively as
NVAS v. placebo.
To test the effect of NVAS on overall cytokine responsiveness
irrespective of stimulation, a collective test for each of the
in vitro cytokines was performed for distributions with <50%
measurements below LLD, except for cytokines where the
effect estimates across the different stimulations in the particular
analysis were too heterogeneous (P< 0·05) to be combined.
The effect of NVAS was analysed overall and stratiﬁed by sex.
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Ethics
In both the NVAS trial and the immunological MV sub-group
study, the mothers were informed by a trained ﬁeld worker
about the studies in their own language, Portuguese Creole,
and, provided consent was given, they were asked to sign or
ﬁngerprint the consent form. The studies adhered to the
Helsinki Declaration. The protocols of the respective studies
were approved by the Ministry of Health in Guinea-Bissau,
and the Danish Central Ethical Committee gave its consultative
approval.
Results
In total, the study included 247 infants, who enrolled in both the
NVAS RCT and in the immunological MV sub-group study to the
early MV trial (Fig. 1). The infants included in the present
analysis only represent a fraction of the participants in the NVAS
trial. To assess whether a particular selection of the cohort had
taken place, we therefore compared background characteristics
of the herein analysed infants with the participants enrolled in
the NVAS trial during the same period, but not included in the
present study. There were only very subtle differences between
Invited to NVAS trial
November 2004 – May 2007
n 6053
Excluded
n 5
Not in
NVAS trial
n 234
Not assessed for
enrolment into
immunological MV
study
n 5054
Randomised in
NVAS trial
n 6048
(2015/2011/2022)
Assessed for enrolment
into immunological
MV study
January 2006 – September 2006
n 1108
Invited to immunological MV study
and participated in NVAS trial
n 874
(301/285/288)
Accepted and passed
inclusion criteria
n 340
(119/114/107)
Capillary blood sample obtained
at baseline
n 249
(88/83/78)
Excluded due to venous sample
n 67
Lost to follow-up
n 24
No consent obtained
n 5
Failed health inclusion criteria*
n 286
Randomised to no inclusion†
n 138
Not included due to limited capacity
n 105
Blood sample analysed‡
n 247
(88/82/77)
Randomised to
NVAS 15 mg RE v.
NVAS 7·5 mg RE v.
placebo
DTP 1–3
Enrolment into in
early MV trial
Birth 6 10 14 weeks 4½ months
Fig. 1. Flow chart of participants and timeline of studies. Numbers in parentheses indicate the number of infants randomised to either of the three treatment arms: 30mg
retinol equivalents (RE) (50000 IU vitamin A)/7·5mg RE (25000 IU vitamin A)/placebo. NVAS, neonatal vitamin A supplementation; MV, measles vaccine; DTP, diphtheria–
tetanus–pertussis vaccine; , blood sample used in the present study. * Health exclusion criteria were as follows: current fever or diarrhoea reported by the mother; an
axillary temperature above 37·5°C; a respiratory rate at 60/min or above; or current infection diagnosed by the examining physician. † As the Early MV trial randomised infants
1:2 to early MV v. no early MV at 4·5 months of age, half of the children in the control arm of the early MV trial were randomised off inclusion to the immunological MV sub-
group study, in order to achieve an equal number of infants in the immunological study in the early MV and no early MV groups, respectively. ‡ Of the total analysed blood
samples, 240 had a plasma sample for ex vivo inflammatory marker analysis, and 208 had an in vitro-stimulated blood sample for cytokine response analysis.
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the analysed infants and the non-analysed infants, the former
being slightly smaller (online Supplementary Table S2), and,
importantly, of the analysed infants, the NVAS and placebo
groups were similar with respect to characteristics presented in
Table 1, which could inﬂuence the immune system at the age of
4–6 months (Table 1).
Sex differences in the placebo group
In the placebo group, there were strong differences between
males and females. Females were less likely than males to have
a BCG scar (71 v. 93%, proportion ratio of no scar: 1·21; 95% CI
1·05, 1·40). Females produced lower IFN-γ responses and
higher IL-10 responses than males did, resulting in lower pro- to
anti-inﬂammatory TNF-α:IL-10 ratios and IFN-γ:IL-10 ratios,
reaching signiﬁcance for the collective cytokine test (online
Supplementary Fig. S1). There were no signiﬁcant sex differ-
ences in plasma cytokine levels in the placebo group (data not
shown), except for higher IL-1Ra levels in females (GMR: 1·19;
95% CI 1·00–1·40).
Effects of neonatal vitamin A supplementation
Females receiving NVAS were signiﬁcantly more likely to have
BCG scars than the placebo group (96 v. 71%, PR: 1·24; 95% CI
1·09–1·42). There was no such difference among males (PR: 1·02;
95% CI 0·95–1·10, P=0·01 for interaction between NVAS and sex).
In males, NVAS was associated with a signiﬁcantly increased
in vitro IL-10 to PPD (GMR: 1·99; 95% CI 1·10, 3·58), to LPS
(GMR: 1·45; 95% CI 1·02, 2·06), and for all stimulations analysed
collectively, but not in females (Fig. 2). The interaction between
NVAS and sex was signiﬁcant for IL-10 responses analysed
collectively (P= 0·002). Moreover, the association of NVAS with
the TNF-α:IL-10 ratios was sex-differential with NVAS tending to
increase the rations in females, but decreasing them in males,
resulting in signiﬁcant interactions between NVAS and sex for
PPD (P= 0·05), TT (P= 0·04), medium alone (P= 0·03) and for
the ratios analysed collectively irrespective of the stimulation
(P= 0·02). A similar pattern was observed for the IFN-γ:IL-10
and IFN-γ:IL-5 ratios, where NVAS was associated with reduced
ratios in males exclusively, signiﬁcantly so for IFN-γ:IL-10 to
PHA (GMRR NVAS-to-placebo: 0·40; 95% CI 0·16, 0·96) and
PPD (GMRR: 0·33; 95% CI 0·13, 0·88), albeit the interaction with
sex was not signiﬁcant. In males but not in females, IL-17
responses to PHA (GMR: 1·69; 95% CI 1·10, 2·59) and for all
stimulations analysed collectively were higher in NVAS than
placebo recipients (Fig. 2).
For plasma biomarkers, NVAS was associated with increased
IL-1Ra in males (GMR: 1·16; 95% CI 1·01, 1·34), but not in
females (GMR: 0·96; 95% CI 0·81, 1·14, Pfor interaction= 0·10).
NVAS was not associated with other plasma cytokine levels in
either sex (data not shown).
Discussion
The present study indicates long-lasting effects of NVAS on
responses to BCG vaccination and immunological responsiveness
of peripheral blood cells persisting at 4–6 months of age in a
Table 1. Population characteristics
(Percentages and numbers; median values and 10th–90th percentiles; mean values and standard deviations)
NVAS Placebo
Observations
Background parameters % n % n P *
All (n) 170 77
Male 55 94 60 46 0·51
Age (d) 0·06
Median 146 149
10th–90th percentile 140–165 141–172
Breast-feeding 95 161 96 74 0·64
Breast-feeding exclusively 27 46 32 24 0·47
Previously hospitalised 2 4 3 2 0·91
OPV at birth 100 170 100 77 –
OPV in campaign 14 24 16 12 0·76
BCG vaccine 100 170 100 77 –
Weight (kg) 0·11
Mean 7·2 7·4
SD 0·8 0·9
Height (cm) 0·42
Mean 64 64
SD 2 2
MUAC (mm) 0·07
Mean 144 147
SD 11 12
Dry season at sampling 28 47 34 26 0·33
Toilet indoor 15 26 14 11 0·84
NVAS, neonatal vitamin A supplementation; OPV, oral polio vaccine; BCG, bacille Calmette–Guérin; MUAC, mid-upper arm circumference.
* Statistical test comparing NVAS with placebo using Kruskal–Wallis test for non-normal numerical data, Student’s t test for normal numerical data
and χ2 test for categorical data.
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sex-dependent manner. NVAS v. placebo was associated with
increased frequency of BCG scars in females, making scar fre-
quencies in NVAS-receiving females comparable to those of boys
in general. NVAS was also associated with more pro-inﬂammatory
cytokine responses in females, whereas the opposite tendency
was seen in males. Sex differences in NVAS effects were found for
responses to several recall antigens and for baseline secretion in
non-stimulated cells, suggesting generalised sex-dependent
immune-modulatory properties of NVAS. Except for IL-1Ra,
plasma inﬂammatory markers were not associated with NVAS,
indicating that the effects observed for in vitro responses were not
due to differences in systemic inﬂammation at the time of bleeding.
Strengths and weaknesses
The investigation of immunological effects of NVAS was con-
ducted in a relevant cohort of infants in a low-income high
disease burden setting, with a documented high proportion of
individuals with low vitamin A levels(15), and hence a potential
target for VAS distribution. The data were generated in a cohort
of infants previously randomised to VAS or placebo, and an
overall balanced distribution of background factors remained in
the present group of participants at blood sampling.
The immunological study, however, was not planned before
conducting the NVAS trial; the samples were collected in con-
nection to a subsequent immunological MV sub-group study of
shorter duration and smaller size, inevitably implying that only a
minor sub-group of the NVAS trial participants were followed
up. Therefore, a biased selection of individuals cannot be ruled
out, although the available background characteristics from the
NVAS trial do not indicate any particular selection. The immu-
nological assay was designed to explore potential non-speciﬁc
immunological effects of early MV on cytokine recall responses
to heterologous vaccines in addition to typical innate stimula-
tion, investigating Th1-, Th2- and Th17-related responses.
Although the assessment of the thirty different stimulation-
cytokine combinations entailed a considerable risk of chance
ﬁndings, we did not use adjustment for multiple testing owing
to the explorative nature of the study. The ﬁndings should be
interpreted with this potential caveat in mind. However, the
overall rather consistent sex-differential pattern of NVAS
dependent cytokine responses is unlikely to be a spurious
IL-13 IL-17
Medium3
PHA
PPD
TT
Collective
Medium3
PHA
PPD
TT
Collective
Medium3
PHA
PPD
TT
Pam
Medium1
LPS
Collective
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
Medium3
PHA
PPD
TT
Collective
Medium3
PHA
PPD
TT
Collective
Medium3
PHA
PPD
TT
Pam
Medium1
LPS
Collective
PHA
PPD
TT
Pam
Medium1
LPS
Collective
PHA
PPD
TT
Collective
IL-10
0.5 1.0 2.0 0.5 1.0 2.0 0.5 1.0 2.0
TNF-
IL-5IFN-γ
IFN-:IL-5 IFN-:IL-10
TNF-:IL-10
*
*
*
*
*
*
*
*
*
*
*
(a) (b)
(c) (d)
(e) (f) (h)
(g)
†
†
††
†
†
Fig. 2. Effects of neonatal vitamin A supplementation on in vitro cytokine responses at the age of 4–6 months, stratified by sex. (a–f) Geometric mean ratios (GMR) of
cytokine responses, comparing NVAS with placebo, stratified by sex. For responses of IL-13, IL-17, IL-10, IFN-γ and IL-5 in the medium 3 condition and IL-17 to
purified protein derivative from Mycobacterium tuberculosis (PPD), >50% of measurements were below the lower detection limit; hence, these outcomes were
analysed as the frequency of measureable values by Poisson regression, and reported as proportion ratios of measurements being above the lower limit. (g and h)
GMR-ratios (GMRR) of cytokine responses TNF-α:IL-10 (g) or IFN-γ:IL-5 and IFN-γ:IL-10 (h), comparing NVAS with placebo; only cytokine distributions with >50%
detectable observations were included in the analysis. A GMR or GMRR >1 can be interpreted as an increasing effect of NVAS on cytokine concentrations or ratios,
respectively. Note that the x-axes for IL-13, IL-17 and IFN-γ and IL-5 are identical. Medium3, medium1: culture with medium alone for 3 or 1 d, respectively; PHA,
phytohaemagglutinin; TT, tetanus toxoid; collective: cytokine responses were analysed collectively, grouped across the different stimulations, excluding outcomes with
<50% measurements within detection ranges of the assay; Pam, palmitoyl(3)-cysteine-serine-lysine(4); LPS, lipopolysaccharide; , Males; , females. Statistical
test for effect of NVAS: * P<0·05; *** P< 0·001; statistical test for interaction between NVAS and sex: † P< 0·05; †† P< 0·01.
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association owing to multiple testing. By inherent limitations of
the assay, cellular sources of the measured cytokines could not
be elucidated, hence hampering a mechanistic interpretation.
Comparison with other studies
Sex differences in basic immunological parameters in
infancy have been reported previously, including higher NK
cell counts and increased inﬂammatory in vitro responses to
LPS and mitogen stimulation in males(16). A recent Gambian
study in a cohort where VAS is routinely given at 6 months
(KL Flanagan, personal communication) found reduced type-1
T-cell reactivity in females compared with males at 10 months
of age (1 month after DTP vaccination), as evidenced by lower
IL-12p70 responses and IFN-γ:IL-4 ratios in unspeciﬁc
T-cell stimulation(17). This seemingly contrasts the elevated
IFN-γ:IL-5 ratios to TT and PPD in females compared with
males among the NVAS recipients in the present fully DTP
vaccinated cohort. However, in likening with the DTP arm of
the Gambian study, the present study found no sex differences
among NVAS recipients in the TNF-α:IL-10 ratios to LPS,
TT or PPD.
In addition to sex differences per se, sex differences in
immunological effects of VAS in children have also been
described, although the evidence of the effects is not unam-
biguous in the literature. A previous study from Guinea-Bissau
reported no effect of NVAS on BCG scar frequencies at 2 and
6 months overall or by sex, as both males and females had high
scar frequencies also in the placebo group. NVAS was asso-
ciated with increased in vitro IFN-γ responses to PPD in males
at 6 weeks, but had no effect on IL-10 responses to PPD; NVAS
was also associated with a transiently lower proportion of
tuberculin skin test responders at 2 months among males, but
not females(18). Another study from Guinea-Bissau evaluating
the immunological effect of NVAS 6 weeks after administration
found the strongest effects of NVAS in DTP-vaccinated males.
NVAS reduced TNF-α and IL-10 secretion in medium alone in
males with prior DTP, but not in females(19). A third immuno-
logical study from Guinea-Bissau investigating the effect of VAS
v. placebo administered together with MV in >6-month-old
children found that VAS tended to decrease all measured
cytokine responses to PHA (TNF-α, IL-10, IL-2, IL-5 and IFN-γ)
in females, but not in males, six weeks after administration; this,
however, was exclusively found in infants, who had not pre-
viously received VAS(13). Overall, these previous ﬁndings are
not unequivocally corroborated by the present study at
4·5 months of age, in which all infants had received three doses
of DTP; herein, NVAS was associated with anti-inﬂammatory
responses in males, but with pro-inﬂammatory responses in
females.
Part of the discrepancy may be attributed to differences in
age of VAS receipt, as VAS at birth v. VAS at 6 months may have
different sex-dependent health effects, or differences in age of
sampling and interaction with vaccination(20). In the immuno-
logical MV sub-group study from which the present study data
used the baseline samples, infants were randomised to receiv-
ing early MV or no early MV (equal distribution of NVAS and
placebo infants). We have previously published that six weeks
after randomisation, MV was associated with increased TNF-α:
IL-10 ratios in infants who had previously received NVAS,
whereas MV tended to decrease the ratios in children without
previous NVAS. This pattern, however, was not signiﬁcantly
different between males and females(11). Hence, MV may
enhance the pro-inﬂammatory effect of NVAS in females,
whereas MV may ameliorate the anti-inﬂammatory effect of
NVAS in males. The latter would be in keeping with the
Gambian infant study, in a setting where VAS is routinely dis-
tributed at 6 months, and where MV at 9 months of age was
associated with enhanced pro-inﬂammatory marker levels in
plasma and responses to TLR4 agonist and PPD stimulation in
males but not in females 1 month after MV compared with the
pre-MV baseline(17).
In the trial of early MV using all-cause mortality as an out-
come, NVAS-receiving females tended to beneﬁt from early MV
(as compared with no early MV), whereas early MV was detri-
mental for NVAS-receiving males(10). A combined analysis of
three NVAS RCT in Guinea-Bissau, including the present,
found that the overall mortality effect of NVAS was signiﬁcantly
sex-differential, with increased female mortality(6), which may
be caused by a negative interaction with DTP(9). Hence, in
females, NVAS v. placebo may be associated with increased
pro-inﬂammatory responsiveness and an increased mortality
risk after DTP, whereas the increased pro-inﬂammatory
responsiveness after MV in NVAS recipients seems not to be
associated with increased mortality risk in females. Further
studies are needed to potentially reconcile these seemingly
contrasting immunological and survival effects of NVAS and
vaccines.
Interestingly, in the same setting, NVAS has also been asso-
ciated with an increased risk of atopy in older children. In two
follow-up studies in Bissau in children aged 3–9 years and 8–10
years who previously enrolled in trials of VAS at birth (in low-
birth weight and normal-birth weight infants, respectively),
NVAS v. placebo was associated with increased risk of atopy
(skin prick test) and wheezing, although in the latter study this
association was exclusively seen in females(21,22). Studies on the
potential associations between cytokine responses and sub-
sequent risk for development of atopic diseases are not
unambiguous; however, a large body of evidence indicates that
Th2-biased and IFN-γ-reduced cytokine response proﬁles in
cord blood and infancy are be associated with increased risk
of development of atopy in childhood (e.g. (23,24)); for example,
in a prospective cohort study, decreased IFN-γ:IL-4 and
IFN-γ:IL-10 response ratios of PMA/ionomycin-stimulated PBMC
in very young infants with eczema were associated with
increased risk of asthma at 4 years of age(25). In the present
cytokine study, NVAS tended to drive cytokine responses
towards a Th2-bias, but in males only, potentially suggesting
sex-differential associations between NVAS, cytokine patterns
and atopic disease.
In conclusion, the present study corroborates sex-differential
effects of VAS on the immune system, ﬁnding that NVAS was
associated with an increased scar formation after BCG vacci-
nation and increased pro- to- anti-inﬂammatory cytokine
response ratios in females, but not in males, emphasising the
importance of analysing VAS effects by sex.
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